Experts Testify to FDA on Psilocybin Research and Treatment
1 report, 1 independent
Updated Sep 20
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
On September 20, 2026, experts testified before the Food and Drug Administration regarding psilocybin research. The testimony involved faculty from Dartmouth College and the National Academy of Medicine. The discussion focused on psilocybin-assisted treatment.
From newsroomamerica.com
Why it matters
The testimony addresses the ongoing evaluation of psychedelic medicine for medical applications. This process contributes to the FDA's review of new therapeutic agents and their potential market pathways.
From newsroomamerica.com
Who's involved
- FDAThe Food and Drug Administration, the body receiving expert testimony.
- Dartmouth CollegeProvided expert testimony regarding psilocybin research.
- National Academy of MedicineProvided expert testimony regarding psilocybin research.
Keep exploring
The entities involved
-
FDA
- The FDA is currently reviewing Medtronic's submission for its MiniMed 780G system, specifically regarding its use for Type 2 diabetes and label expansion into Europe.
- The Dietary Supplement Health and Education Act established the regulatory framework, with FDA oversight affecting the supplement industry.
-
Dartmouth College
private university in Hanover, New Hampshire, US
-
National Academy of Medicine
medical branch of the United States National Academies
Nothing else this week.